Search Prime Grants

U54CA231637

Cooperative Agreement

Overview

Grant Description
The center for therapeutic targeting of EWS-oncoproteins.
Awardee
Dana-Farber Cancer Institute
Funding Goals
TO PROVIDE AN ORGANIZATIONAL FOCUS AND STIMULUS FOR THE HIGHEST QUALITY CANCER RESEARCH THAT EFFECTIVELY PROMOTES INTERDISCIPLINARY CANCER RESEARCH AIMED TOWARD THE ULTIMATE GOAL OF REDUCING CANCER INCIDENCE, MORTALITY AND MORBIDITY. THE CANCER CENTER SUPPORT GRANT (CCSG) PROVIDES THE RESOURCES AND INFRASTRUCTURE TO FACILITATE THE COORDINATION OF INTERDISCIPLINARY PROGRAMS ACROSS A BROAD SPECTRUM OF RESEARCH FROM BASIC LABORATORY RESEARCH TO CLINICAL INVESTIGATION TO POPULATION SCIENCE. THE CCSG SUPPORTS SALARIES FOR SCIENTIFIC LEADERSHIP OF THE CENTER, SHARED RESOURCES FOR FUNDED CENTER INVESTIGATORS, CERTAIN ADMINISTRATIVE COSTS, PLANNING AND EVALUATION, AND DEVELOPMENTAL FUNDS FOR NEW RECRUITMENTS AND FEASIBILITY STUDIES.
Grant Program (CFDA)
93.397 - Cancer Centers Support Grants
Awarding / Funding Agency
National Cancer Institute (NCI) [HHS - NIH]
Place of Performance
Boston, Massachusetts 02215 United States
Geographic Scope
Single Zip Code
Related Opportunity
Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) (PA-20-272)
Analysis Notes
Amendment Since initial award the End Date has been extended from 06/30/23 to 06/30/24 and the total obligations have increased 6% from $12,500,000 to $13,203,098.
Dana-Farber Cancer Institute was awarded The Center for Therapeutic Targeting of EWS-oncoproteins Cooperative Agreement U54CA231637 worth $13,203,098 from National Cancer Institute in September 2018 with work to be completed primarily in Boston Massachusetts United States. The grant has a duration of 5 years 9 months and was awarded through assistance program 93.397 Cancer Centers Support Grants. The Cooperative Agreement was awarded through grant opportunity Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional).

Status
(Complete)

Last Modified 11/7/24

Period of Performance
9/10/18
Start Date
6/30/24
End Date
100% Complete

Funding Split
$13.2M
Federal Obligation
$0.0
Non-Federal Obligation
$13.2M
Total Obligated
100.0% Federal Funding
0.0% Non-Federal Funding

Activity Timeline

Interactive chart of timeline of amendments to U54CA231637

Subgrant Awards

Disclosed subgrants for U54CA231637

Transaction History

Modifications to U54CA231637

Additional Detail

Award ID FAIN
U54CA231637
SAI Number
U54CA231637-667890087
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Nonprofit With 501(c)(3) IRS Status (Other Than An Institution Of Higher Education)
Awarding Office
75NC00 NIH NATIONAL CANCER INSTITUTE
Funding Office
75NC00 NIH NATIONAL CANCER INSTITUTE
Awardee UEI
DPMGH9MG1X67
Awardee CAGE
5E915
Performance District
MA-07
Senators
Edward Markey
Elizabeth Warren

Budget Funding

Federal Account Budget Subfunction Object Class Total Percentage
National Cancer Institute, National Institutes of Health, Health and Human Services (075-0849) Health research and training Grants, subsidies, and contributions (41.0) $25,505,427 100%
Modified: 11/7/24